OTL38
Phase 1Small molecule
OTL38 is one of 109 small molecule programs targeting Adenoma. It is currently in Phase 1.
3
Indications
7
Total Trials
0
Active Trials
108
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Hycamtin
MMeitheal
Phase 3
Femara
NovartisPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Perjeta
RochePhase 3
Tylenol
KKenvue Brands
Phase 3
IV Iron
PfizerPhase 3
Salvage Chemotherapy
Daiichi SankyoPhase 3
H1 Receptor Antagonist
Merck & Co.Phase 3
Karenitecin
BBioNumerik Pharmaceuticals, Inc.
Phase 3
In Vitro Sensitivity-Directed Chemotherapy
CChildren's Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ovarian Cancer3 trials
OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer
Withdrawn·—·Phase 1·NCT04941378
Solid Tumor Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OTL38. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Pennsylvania